Global Short Bowel Syndrome Market - 2022-2029

Market Overview

Short bowel syndrome market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 15.9 % during the forecast period (2022-2029).

Short bowel syndrome (SBS) is a metabolic disorder that occurs due to the malfunctioning or removal of the small intestine through surgery due to digestive illness. The consequences may be malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.

Market Dynamics

The growth of the short bowel syndrome market is due to rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohn's disease (CD), which predisposes patients to development of SBS and mesenteric ischemia are the most common causes for SBS among all the age groups which demand the necessity of the treatment and high cost of parenteral nutrition increases demand for SBS drugs.

High cost of parenteral nutrition increases demand for SBS drugs is expected to hold the largest share in this market segment

Most of the short bowel syndrome patients are on parenteral nutrition initially until the patients' intestine has adopted and hemostasis is being maintained. The cost of parenteral nutrition varies from patient to patient, and ranges between US$ 150,000 and US$ 586,000 per year. High cost of parenteral nutrition increases the demand for short bowel syndrome drugs, which have shown the ability to reduce patient's dependence on parenteral nutrition during clinical trials.

For instance, Feb. 3, 2021, VectivBio Holding AG, apraglutide has the potential to enable patients to minimize the burden from parenteral support by increasing intestinal absorption of fluids, calories, and nutrients. The phase 3 STARS (STudy of ApRaglutide in SBS) trial is a global clinical trial that represents the largest phase 3 trial ever conducted in short bowel syndrome with intestinal failure (SBS-IF). STARS is the first trial of a next-generation, long-acting GLP-2 analog, designed to exclusively evaluate a once-weekly dosing interval and to take into account remnant bowel anatomy and individual caloric needs during weaning patients off of parenteral support.

High cost of treatment is likely to hamper the market growth

The cost of treatment of rare diseases is significantly high, which makes the treatment unaffordable for low-income groups. Additionally, lack of reimbursement in certain countries renders the treatment unreachable to several target group people.

For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved extending the indication of GITEX (teduglutide) for injection to pediatric patients 1 year of age and older with short bowel syndrome (SBS). Gattex (teduglutide) is an injectable drug used to treat adults with short bowel syndrome (SBS). Gattex is quite expensive, with treatment costing over US$ 295,000 a year. The cost of treatment for the lifetime renders the treatment unaffordable, as rare diseases are life-threatening and do not have a permanent cure, thereby leading to a decline in the number of patients preferring to avail the treatment.

COVID-19 Impact Analysis

Since patients with COVID-19 have reported gastrointestinal symptoms, such findings are creating additional revenue opportunities for manufacturers in the short bowel syndrome market. However, the SBS treatment requires long-term parenteral nutrition or an organ transplant. Hence, companies should collaborate with researchers to increase the study in autologous tissue engineering, which helps in treating an individual using their own cells or tissues. Companies are boosting their output capacities in anti-secretin agents to help patients reduce gastric acid in the intestine, growth hormones, and hypomotility agents to increase the time it takes the food to travel through intestines, resulting in increased nutrient absorption.

Segment Analysis

The GLP-2 drug therapy segment is expected to hold the largest share in this market segment

The GLP-2 drug treatment accounts for the major market share throughout the forecast period. The dominance is due to the only products available for treatment with the brand names Gattex and Revestive, introduced by Takeda which were approved for sales in both the US and Europe respectively. Also, the patent exclusivity of GLP-2 drug is anticipated to contribute to its significant share in the revenue of the global short bowel syndrome market.

For instance, Takeda Pharmaceuticals, on May 2019, announced that the US FDA approved extending the indication of GATTEX (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support).

Geographical Analysis

North America region holds the largest market share of global short bowel syndrome market

North America is expected to major share of overall Short Bowel Syndrome Market throughout the forecast period. This dominance is mainly due to the revenue generated by the Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders are a major factor that drives the market growth in the region.

Competitive Landscape

The global short bowel syndrome market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Takeda Pharmaceutical Company Limited, OxThera Inc, VectivBio AG, Nutrinia, Merck KGaA, Pfizer Inc, Ardelyx, Zealand Pharma and Nestle S.A. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the short bowel syndrome globally. For instance, In December 2020, 9 Meters Biopharma, Inc. announced positive topline results from its open-label phase 1b/2a clinical trial evaluating NM-002, its proprietary long-acting glucagon-like peptide-1 (GLP-1) receptor agonist in adults with short bowel syndrome (SBS). NM-002 is designed as a long-acting injectable GLP-1 receptor agonist that utilizes proprietary XTEN technology to extend circulating half-life. This is designed specifically to slow digestive transit time in SBS patients by reducing upper GI motility and improve the chronic diarrhea associated with a shortened intestine.

Key Companies to Watch

Takeda Pharmaceutical Company Limited

Overview: The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.

Product Portfolio: GATTEX (teduglutide) for subcutaneous injection is a prescription medicine used in adults and children 1 year of age and older with Short Bowel Syndrome (SBS).

Why Purchase the Report?

• Visualize the composition of the short bowel syndrome market segmentation by drug class, distribution channel, and region highlighting the key commercial assets and players.
• Identify commercial opportunities in short bowel syndrome market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of short bowel syndrome market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players.

The global short bowel syndrome market report would provide an access to an approx. 47 market data table, 41 figures and 180 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers